tbuckley/cabot-search huggingface dataset:
The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial
Authors: Mathias Witzens-Harig, Andreas Viardot, Ulrich Keller, Julia Wosniok, Oliver Deuster, Jennifer Klemmer, Anne-Marie Geueke, Julia Meißner, Anthony D. Ho, Johannes Atta, Reinhard Marks, Paul La Rosée, Christian Buske, Martin H. Dreyling, Georg Hess
Journal: HemaSphere (2021)

There is a high need for novel treatment options in relapsed and refractory diffuse large B-cell lymphoma. Single agent mammalian target of rapamycin (mTOR) inhibitor treatment has shown promising efficacy in this entity. Here, we report on the results of the mTOR-inhibitor temsirolimus combined to standard rituximab-DHAP salvage regimen in a prospective, multicenter, phase II, open-label study. The STORM regimen consisted of rituximab 375 mg/m 2 (day 2) and DHAP (dexamethasone 40 mg day 3-6, cisplatinum 100 mg/m 2 day 3, cytarabine 2 × 2 g/m 2 day 4) with temsirolimus added on day 1 and 8 of a 21-day cycle, with 2 to 4 cycles planned. In part I, dose levels of 25, 50, 75, and 100 mg for temsirolimus were predefined. Based on the observed toxicity profile, a temsirolimus dose of 25 mg was defined as recommended dose for the part II extension cohort of the trial. The intention-to-treat cohort comprised 53 patients. Median age was 63 years and median number of prior regimen was 1. All but 1 patient had prior rituximab exposure. Temsirolimus dose was 50 mg on day 1 and 8 in 6 patients from the part I of the trial and 25 mg in the remaining 47 patients. In general, treatment was well tolerated with leucopenia and thrombocytopenia as most frequent severe adverse events. The overall response rate after the last cycle of temsirolimus R-DHAP was 66% with 24% complete responses. The ability to mobilize stem cells was not impaired by the treatment regimen. Twenty-eight patients received consolidation treatment with high-dose therapy (HDT) and stem cell transplantation. Median duration of response was not reached. The total 2-year progression-free survival (PFS) and overall survival (OS) were 53% and 59%. Patients who were consolidated with HDT achieved a 2-year PFS and a 2-year OS of 77.8% and 82.1%, respectively. We conclude that temsirolimus can be safely added to rituximab and DHAP with promising activity.
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial*
Authors: M. Goebeler, Z. Bata‐Csörgő, C. De Simone, B. Didona, E. Remenyik, N. Reznichenko, J. Stoevesandt, E.S. Ward, W. Parys, H. de Haard, P. Dupuy, P. Verheesen, E. Schmidt, P. Joly
Journal: British Journal of Dermatology (2021)

Pemphigus vulgaris and pemphigus foliaceus are potentially life-threatening autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal desmogleins. There is an unmet need for fast-acting drugs that enable patients to achieve early sustained remission with reduced corticosteroid reliance.To investigate efgartigimod, an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor, thereby reducing serum IgG levels, for treating pemphigus.Thirty-four patients with mild-to-moderate pemphigus vulgaris or foliaceus were enrolled in an open-label phase II adaptive trial. In sequential cohorts, efgartigimod was dosed at 10 or 25 mg kg-1 intravenously with various dosing frequencies, as monotherapy or as add-on therapy to low-dose oral prednisone. Safety endpoints comprised the primary outcome. The study is registered at ClinicalTrials.gov (identifier NCT03334058).Adverse events were mostly mild and were reported by 16 of 19 (84%) patients receiving efgartigimod 10 mg kg-1 and 13 of 15 (87%) patients receiving 25 mg kg-1 , with similar adverse event profiles between dose groups. A major decrease in serum total IgG and anti-desmoglein autoantibodies was observed and correlated with improved Pemphigus Disease Area Index scores. Efgartigimod, as monotherapy or combined with prednisone, demonstrated early disease control in 28 of 31 (90%) patients after a median of 17 days. Optimized, prolonged treatment with efgartigimod in combination with a median dose of prednisone 0·26 mg kg-1 per day (range 0·06-0·48) led to complete clinical remission in 14 of 22 (64%) patients within 2-41 weeks.Efgartigimod was well tolerated and exhibited an early effect on disease activity and outcome parameters, providing support for further evaluation as a therapy for pemphigus.
446P Bayesian monitoring of lapatinib (L) plus trastuzumab (T) treatment of HER2 positive metastatic colorectal cancer (mCRC): An observational cohort study
Authors: A. Amatu, S. Ghezzi, C. Vaghi, G. Mauri, K. Bencardino, F. Tosi, E. Bonazzina, V. Gori, F. Bolazzi, S. Siena, A. Sartore-Bianchi
Journal: Annals of Oncology (2021)
An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models
Authors: Bert Schepens, Loes van Schie, Wim Nerinckx, Kenny Roose, Wander Van Breedam, Daria Fijalkowska, Simon Devos, Wannes Weyts, Sieglinde De Cae, Sandrine Vanmarcke, Chiara Lonigro, Hannah Eeckhaut, Dries Van Herpe, Jimmy Borloo, Ana Filipa Oliveira, João Paulo Portela Catani, Sarah Creytens, Dorien De Vlieger, Gitte Michielsen, Jackeline Cecilia Zavala Marchan, George D. Moschonas, Iebe Rossey, Koen Sedeyn, Annelies Van Hecke, Xin Zhang, Lana Langendries, Sofie Jacobs, Sebastiaan ter Horst, Laura Seldeslachts, Laurens Liesenborghs, Robbert Boudewijns, Hendrik Jan Thibaut, Kai Dallmeier, Greetje Vande Velde, Birgit Weynand, Julius Beer, Daniel Schnepf, Annette Ohnemus, Isabel Remory, Caroline S. Foo, Rana Abdelnabi, Piet Maes, Suzanne J. F. Kaptein, Joana Rocha-Pereira, Dirk Jochmans, Leen Delang, Frank Peelman, Peter Staeheli, Martin Schwemmle, Nick Devoogdt, Dominique Tersago, Massimiliano Germani, James Heads, Alistair Henry, Andrew Popplewell, Mark Ellis, Kevin Brady, Alison Turner, Bruno Dombrecht, Catelijne Stortelers, Johan Neyts, Nico Callewaert, Xavier Saelens
Journal: Science Translational Medicine (2021)

Broadly neutralizing antibodies are an important treatment for individuals with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Antibody-based therapeutics are also essential for pandemic preparedness against future Sarbecovirus outbreaks. Camelid-derived single domain antibodies (VHHs) exhibit potent antimicrobial activity and are being developed as SARS-CoV-2–neutralizing antibody-like therapeutics. Here, we identified VHHs that neutralize both SARS-CoV-1 and SARS-CoV-2, including now circulating variants. We observed that the VHHs bound to a highly conserved epitope in the receptor binding domain of the viral spike protein that is difficult to access for human antibodies. Structure-guided molecular modeling, combined with rapid yeast-based prototyping, resulted in an affinity enhanced VHH-human immunoglobulin G1 Fc fusion molecule with subnanomolar neutralizing activity. This VHH-Fc fusion protein, produced in and purified from cultured Chinese hamster ovary cells, controlled SARS-CoV-2 replication in prophylactic and therapeutic settings in mice expressing human angiotensin converting enzyme 2 and in hamsters infected with SARS-CoV-2. These data led to affinity-enhanced selection of the VHH, XVR011, a stable anti–COVID-19 biologic that is now being evaluated in the clinic.
Multiomics reveal unique signatures of human epiploic adipose tissue related to systemic insulin resistance
Authors: Laura Krieg, Konrad Didt, Isabel Karkossa, Stephan H Bernhart, Stephanie Kehr, Narmadha Subramanian, Andreas Lindhorst, Alexander Schaudinn, Shirin Tabei, Maria Keller, Michael Stumvoll, Arne Dietrich, Martin von Bergen, Peter F Stadler, Jurga Laurencikiene, Martin Krüger, Matthias Blüher, Martin Gericke, Kristin Schubert, Peter Kovacs, Rima Chakaroun, Lucas Massier
Journal: Gut (2021)

Human white adipose tissue (AT) is a metabolically active organ with distinct depot-specific functions. Despite their locations close to the gastrointestinal tract, mesenteric AT and epiploic AT (epiAT) have only scarcely been investigated. Here, we aim to characterise these ATs in-depth and estimate their contribution to alterations in whole-body metabolism.Mesenteric, epiploic, omental and abdominal subcutaneous ATs were collected from 70 patients with obesity undergoing Roux-en-Y gastric bypass surgery. The metabolically well-characterised cohort included nine subjects with insulin sensitive (IS) obesity, whose AT samples were analysed in a multiomics approach, including methylome, transcriptome and proteome along with samples from subjects with insulin resistance (IR) matched for age, sex and body mass index (n=9). Findings implying differences between AT depots in these subgroups were validated in the entire cohort (n=70) by quantitative real-time PCR.While mesenteric AT exhibited signatures similar to those found in the omental depot, epiAT was distinct from all other studied fat depots. Multiomics allowed clear discrimination between the IS and IR states in all tissues. The highest discriminatory power between IS and IR was seen in epiAT, where profound differences in the regulation of developmental, metabolic and inflammatory pathways were observed. Gene expression levels of key molecules involved in AT function, metabolic homeostasis and inflammation revealed significant depot-specific differences with epiAT showing the highest expression levels.Multi-omics epiAT signatures reflect systemic IR and obesity subphenotypes distinct from other fat depots. Our data suggest a previously unrecognised role of human epiploic fat in the context of obesity, impaired insulin sensitivity and related diseases.
395P Randomized control trial to assess radiological and pathological response after neo adjuvant concomitant chemo radiotherapy vs. sequential short course radiotherapy (SCRT) followed by chemotherapy in locally advanced rectal cancer (LARC)
Authors: W.A. Humayun, M.A. Khokhar, S. Yaqub, A.W. Goraya, A. Akbar, M. Abid
Journal: Annals of Oncology (2021)
451P Utility of circulating free DNA 5’-end motif profile in the prediction of pathological response after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
Authors: Y. Wang, X. Fan, Y. Xu, H. Bao, F. Xia, J. Wan, L. Shen, X. Wu, Y. Shao, X. Li, Y. Xu, S. Cai, Z. Zhang
Journal: Annals of Oncology (2021)
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T <sub>H</sub> 1 response with a diverse TCR repertoire
Authors: Phillip A. Swanson, Marcelino Padilla, Wesley Hoyland, Kelly McGlinchey, Paul A. Fields, Sagida Bibi, Saul N. Faust, Adrian B. McDermott, Teresa Lambe, Andrew J. Pollard, Nicholas M. Durham, Elizabeth J. Kelly
Journal: Science Translational Medicine (2021)

AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus–vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 in clinical trials and real-world studies. We characterized CD4
1318P Neutrophil extracellular traps as a potential predictive marker for treatment with pembrolizumab alone or with chemotherapy as a first-line in patients with metastatic non-small cell lung cancer
Authors: M. Petrova, D. Parvanov, R. Ganeva, D. Metodiev, S. Bachurska, G. Stamenov, M. Eneva, P. Penkova, I. Sarbianova, T. Popov, K. Nikolov, M. Radanova, M. Taushanova, V. Megdanova, I. Donev
Journal: Annals of Oncology (2021)
1334P Efficacy and safety of anlotinib plus docetaxel in non-small cell lung cancer (NSCLC) after failure of previous immune checkpoint inhibitors (ICIs) therapy: Results from a phase I/II trial
Authors: Y. Fang, H. Pan, J. Shou, W. Hong, J. Chen, Y. Wang, Q. Guo, L. Lu, C. Rao, X. Yang, D. Zhu, F. Lan
Journal: Annals of Oncology (2021)
CN46 Oncology clinical nurse specialist versatility: Ensuring a safer, continued day oncology environment throughout COVID
Authors: F.E. Barrett, L. French, D. O'Doherty, C. Matassa, T. Doyle, L. Judge, N. Cooley, A. Geraghty, G. Sheeran, C. O'Shea, O.S. Breathnach, A. Christie
Journal: Annals of Oncology (2021)
918P Impact of locally advanced head and neck cancer treatment: Is there a role for exercise? FIT4TREAT
Authors: I.I.L. Leao, C. Garcia, P. Antunes, A. Campolargo, I. Dias, E. Coimbra, H. Zenha, J. Castro, P. Oliveira, M. Giesteira, H. Costa, A. Alves, A. Capela, A. Joaquim
Journal: Annals of Oncology (2021)
566TiP A first-in-human study of NUC-7738, a ProTide transformation of 3’-deoxyadenosine, in patients with advanced solid tumours (NuTide:701)
Authors: S. Blagden, N.M. Haris, Z. Boh, F. Kazmi, F. Aroldi, M. Myers, S.N. Symeonides, R. Plummer
Journal: Annals of Oncology (2021)
Precisely timed theta oscillations are selectively required during the encoding phase of memory
Authors: Clare R. Quirk, Ipshita Zutshi, Sunandha Srikanth, Maylin L. Fu, Naomie Devico Marciano, Morgan K. Wright, Darian F. Parsey, Stanley Liu, Rachel E. Siretskiy, Tiffany L. Huynh, Jill K. Leutgeb, Stefan Leutgeb
Journal: Nature Neuroscience (2021)
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Authors: Laura Evans, Andrew Rhodes, Waleed Alhazzani, Massimo Antonelli, Craig M. Coopersmith, Craig French, Flávia R. Machado, Lauralyn Mcintyre, Marlies Ostermann, Hallie C. Prescott, Christa Schorr, Steven Simpson, W. Joost Wiersinga, Fayez Alshamsi, Derek C. Angus, Yaseen Arabi, Luciano Azevedo, Richard Beale, Gregory Beilman, Emilie Belley-Cote, Lisa Burry, Maurizio Cecconi, John Centofanti, Angel Coz Yataco, Jan De Waele, R. Phillip Dellinger, Kent Doi, Bin Du, Elisa Estenssoro, Ricard Ferrer, Charles Gomersall, Carol Hodgson, Morten Hylander Møller, Theodore Iwashyna, Shevin Jacob, Ruth Kleinpell, Michael Klompas, Younsuck Koh, Anand Kumar, Arthur Kwizera, Suzana Lobo, Henry Masur, Steven McGloughlin, Sangeeta Mehta, Yatin Mehta, Mervyn Mer, Mark Nunnally, Simon Oczkowski, Tiffany Osborn, Elizabeth Papathanassoglou, Anders Perner, Michael Puskarich, Jason Roberts, William Schweickert, Maureen Seckel, Jonathan Sevransky, Charles L. Sprung, Tobias Welte, Janice Zimmerman, Mitchell Levy
Journal: Intensive Care Medicine (2021)
Neurocognitive outcomes in Malawian children exposed to malaria during pregnancy: An observational birth cohort study
Authors: Andrea M. Weckman, Andrea L. Conroy, Mwayiwawo Madanitsa, Bruno Gnaneswaran, Chloe R. McDonald, Linda Kalilani-Phiri, Jaya Chandna, Doreen Ali, Victor Mwapasa, Carole Khairallah, Kyaw Lay Thwai, Steven R. Meshnick, Steve M. Taylor, Feiko O. ter Kuile, Kevin C. Kain, Melissa Gladstone
Journal: PLoS Medicine (2021)

Annually 125 million pregnancies are at risk of malaria infection. However, the impact of exposure to malaria in pregnancy on neurodevelopment in children is not well understood. We hypothesized that malaria in pregnancy and associated maternal immune activation result in neurodevelopmental delay in exposed offspring.Between April 2014 and April 2015, we followed 421 Malawian mother-baby dyads (median [IQR] maternal age: 21 [19, 28] years) who were previously enrolled (median [IQR] gestational age at enrollment: 19.7 [17.9, 22.1] weeks) in a randomized controlled malaria prevention trial with 5 or 6 scheduled assessments of antenatal malaria infection by PCR. Children were evaluated at 12, 18, and/or 24 months of age with cognitive tests previously validated in Malawi: the Malawi Developmental Assessment Tool (MDAT) and the MacArthur-Bates Communicative Development Inventories (MCAB-CDI). We assessed the impact of antenatal malaria (n [%] positive: 240 [57.3]), placental malaria (n [%] positive: 112 [29.6]), and maternal immune activation on neurocognitive development in children. Linear mixed-effects analysis showed that children exposed to antenatal malaria between 33 and 37 weeks gestation had delayed language development across the 2-year follow-up, as measured by MCAB-CDI (adjusted beta estimate [95% CI], -7.53 [-13.04, -2.02], p = 0.008). Maternal immune activation, characterized by increased maternal sTNFRII concentration, between 33 and 37 weeks was associated with lower MCAB-CDI language score (adjusted beta estimate [95% CI], -8.57 [-13.09, -4.06], p < 0.001). Main limitations of this study include a relatively short length of follow-up and a potential for residual confounding that is characteristic of observational studies.This mother-baby cohort presents evidence of a relationship between malaria in pregnancy and neurodevelopmental delay in offspring. Malaria in pregnancy may be a modifiable risk factor for neurodevelopmental injury independent of birth weight or prematurity. Successful interventions to prevent malaria during pregnancy may reduce the risk of neurocognitive delay in children.
Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021
Authors: Anne M. Hause, James Baggs, Julianne Gee, Paige Marquez, Tanya R. Myers, Tom T. Shimabukuro, David K. Shay
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

On August 12, 2021, the Food and Drug Administration (FDA) amended Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech and Moderna COVID-19 vaccines to authorize administration of an additional dose after completion of a primary vaccination series to eligible persons with moderate to severe immunocompromising conditions (1,2). On September 22, 2021, FDA authorized an additional dose of Pfizer-BioNTech vaccine ≥6 months after completion of the primary series among persons aged ≥65 years, at high risk for severe COVID-19, or whose occupational or institutional exposure puts them at high risk for COVID-19 (1). Results from a phase 3 clinical trial conducted by Pfizer-BioNTech that included 306 persons aged 18-55 years showed that adverse reactions after receipt of a third dose administered 5-8 months after completion of a 2-dose primary mRNA vaccination series were similar to those reported after receipt of dose 2; these adverse reactions included mild to moderate injection site and systemic reactions (3). CDC developed v-safe, a voluntary, smartphone-based safety surveillance system, to provide information on adverse reactions after COVID-19 vaccination. Coincident with authorization of an additional dose for persons with immunocompromising conditions, the v-safe platform was updated to allow registrants to enter information about additional doses of COVID-19 vaccine received. During August 12-September 19, 2021, a total of 22,191 v-safe registrants reported receipt of an additional dose of COVID-19 vaccine. Most (97.6%) reported a primary 2-dose mRNA vaccination series followed by a third dose of the same vaccine. Among those who completed a health check-in survey for all 3 doses (12,591; 58.1%), 79.4% and 74.1% reported local or systemic reactions, respectively, after dose 3, compared with 77.6% and 76.5% who reported local or systemic reactions, respectively, after dose 2. These initial findings indicate no unexpected patterns of adverse reactions after an additional dose of COVID-19 vaccine; most of these adverse reactions were mild or moderate. CDC will continue to monitor vaccine safety, including the safety of additional doses of COVID-19 vaccine, and provide data to guide vaccine recommendations and protect public health.
Abstract 15352: Novel AAV9 Constructs Using SLN and PLN Promoters Act as Specialized Tools for Cardiac Chamber-Specific Transduction
Authors: Alina S Bilal, Erik A Blackwood, Donna J Thuerauf, Christopher C Glembotski
Journal: Circulation (2018)

Introduction: The adeno-associated virus serotype 9 (AAV9) vector exhibits high transduction efficiency and cardiotropism which has allowed for the elucidation of tissue-specific functions of genes...
Incidence and Predictors of Second Primary Cancers in Patients With Neuroendocrine Tumors
Authors: Sarah B. Bateni, Natalie G. Coburn, Calvin H. L. Law, Simron Singh, Sten Myrehaug, Angela Assal, Julie Hallet
Journal: JAMA Oncology (2021)

This retrospective cohort study examines the risk factors and predictors of second primary cancers after being diagnosed with neuroendocrine tumors.
1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047
Authors: F.S. Hodi, H.A. Tawbi, E.J. Lipson, D. Schadendorf, P.A. Ascierto, L. Matamala, E.C. Gutiérrez, P. Rutkowski, H.J. Gogas, C.D. Lao, J.J. De Menezes, S. Dalle, A. Arance, J.J. Grob, L. Toms, K. Jonczak, A.M. Sobiesk, G.V. Long
Journal: Annals of Oncology (2021)
1691P Thromboembolic disease and immunotherapy in lung cancer
Authors: D. Fernandez Garay, N. Blaya Boluda, J. Rubio Pérez, L. Ortega Morán, J. Brenes Castro, Y. Lage, D. Cacho Lavin, C. Guirao Rubio, J. Bosque Moreno, A.M. Martin Fernandez de Soignie, M. Lobo de Mena, B. Obispo Portero, M.C. Rosa Garrido, C. Font Puig, A. Muñoz Martín, M. Sánchez Cánovas
Journal: Annals of Oncology (2021)
Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas
Authors: Pooja Panwalkar, Benita Tamrazi, Derek Dang, Chan Chung, Stefan Sweha, Siva Kumar Natarajan, Matthew Pun, Jill Bayliss, Martin P. Ogrodzinski, Drew Pratt, Brendan Mullan, Debra Hawes, Fusheng Yang, Chao Lu, Benjamin R. Sabari, Abhinav Achreja, Jin Heon, Olamide Animasahun, Marcin Cieslik, Christopher Dunham, Stephen Yip, Juliette Hukin, Joanna J. Phillips, Miriam Bornhorst, Andrea M. Griesinger, Andrew M. Donson, Nicholas K. Foreman, Hugh J. L. Garton, Jason Heth, Karin Muraszko, Javad Nazarian, Carl Koschmann, Li Jiang, Mariella G. Filbin, Deepak Nagrath, Marcel Kool, Andrey Korshunov, Stefan M. Pfister, Richard J. Gilbertson, C. David Allis, Arul M. Chinnaiyan, Sophia Y. Lunt, Stefan Blüml, Alexander R. Judkins, Sriram Venneti
Journal: Science Translational Medicine (2021)

Childhood posterior fossa group A ependymomas demonstrate integrated metabolic and epigenetic pathways that can be disrupted by metformin.
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques
Authors: Pranav Preman, Julia TCW, Sara Calafate, An Snellinx, Maria Alfonso-Triguero, Nikky Corthout, Sebastian Munck, Dietmar Rudolf Thal, Alison M Goate, Bart De Strooper, Amaia M Arranz
Journal: Molecular Neurodegeneration (2021)

Abstract Background Increasing evidence for a direct contribution of astrocytes to neuroinflammatory and neurodegenerative processes causing Alzheimer’s disease comes from molecular and functional studies in rodent models. However, these models may not fully recapitulate human disease as human and rodent astrocytes differ considerably in morphology, functionality, and gene expression. Results To address these challenges, we established an approach to study human astrocytes within the mouse brain by transplanting human induced pluripotent stem cell (hiPSC)-derived astrocyte progenitors into neonatal brains. Xenografted hiPSC-derived astrocyte progenitors differentiated into astrocytes that integrated functionally within the mouse host brain and matured in a cell-autonomous way retaining human-specific morphologies, unique features, and physiological properties. In Alzheimer´s chimeric brains, transplanted hiPSC-derived astrocytes responded to the presence of amyloid plaques undergoing morphological changes that seemed independent of the APOE allelic background. Conclusions In sum, we describe here a promising approach that consist of transplanting patient-derived and genetically modified astrocytes into the mouse brain to study human astrocyte pathophysiology in the context of Alzheimer´s disease.
307P Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer
Authors: E. Blondeaux, L. Boni, T. Ruelle, V. Di Lauro, C. Molinelli, M. Piezzo, B. Fratini, F. Poggio, P. Pugliese, A. Ferzi, G. Buzzatti, S. Russo, O. Garrone, S. Gasparro, A. D'Alonzo, M. De Laurentiis, A. Fabi, G. Arpino, C. Bighin, L. Del Mastro
Journal: Annals of Oncology (2021)